Do the benefits outweigh the risks? Potential dangers associated with long-term therapy of proton pump inhibitors
DOI:
https://doi.org/10.12775/JEHS.2023.26.01.008Keywords
Proton Pump Inhibitors, PPI, side effects, adverse effects, risk factors, long-term use of PPIAbstract
Introduction:Proton pump inhibitors (PPIs) are one of the most popular and also one of the most commonly prescribed medications worldwide. In many conditions associated with excessive secretion of hydrochloric acid in the stomach, they are the first-line treatment. When they are used in a balanced manner in strict indications, they have a high level of efficacy and a favorable safety profile. The low rate of side effects refers mainly to their short-term use. With the over-the-counter availability of PPIs, increasing dangerous trend of their abuse has provided new evidence suggesting the presence of numerous, more serious side effects of long-term PPI therapy.
Purpose:The purpose of this review is to summarize current reports regarding the potential risks and causal relationship of adverse effects occurring as a consequence of long-term use of proton pump inhibitors.
Material and methods:This literature review based on the available scientific literature, published between 2015 and 2023 in the Pubmed database, searched using the terms, listed under "keywords”.
Conclusion:PPIs are relatively safe drugs. However, they are not completely free of side effects. There are a lot of reports suggesting a potential connection between their long-term use and the development of complications, such as: various infections, decreased absorption of nutrients, kidney disease, liver disease, pancreatic disease, musculoskeletal disease, nervous system disease, cardiovascular disease, dementia, hypergastrinemia and even cancer. However, some of them are fraught with errors, and another often provide contradictory results. More precisely designed studies are needed to draw clear conclusions, especially in view of the ever-increasing abuse of PPIs worldwide. It is worth noting that patients with strictly defined indications for long-term PPI therapy, may benefit significantly outweighing the potential dangers.
References
Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017 Jan 15;11(1):27-37. doi: 10.5009/gnl15502. PMID: 27840364; PMCID: PMC5221858.
Fossmark R, Martinsen TC, Waldum HL. Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility. Int J Mol Sci. 2019 Oct 21;20(20):5203. doi: 10.3390/ijms20205203. PMID: 31640115; PMCID: PMC6829383.
Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie. 2021 Jan-Feb;76(1):13-21. doi: 10.1016/j.therap.2020.06.019. Epub 2020 Jul 9. PMID: 32718584.
Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):114-121. doi: 10.1111/bcpt.13023. Epub 2018 May 24. PMID: 29658189.
Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis. 2016 Aug;48(8):851-9. doi: 10.1016/j.dld.2016.05.018. Epub 2016 May 30. PMID: 27321544.
Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. The appropriate use of proton-pump inhibitors. Minerva Med. 2018 Oct;109(5):386-399. doi: 10.23736/S0026-4806.18.05705-1. Epub 2018 May 31. PMID: 29856192.
Lanas A. We Are Using Too Many PPIs, and We Need to Stop: A European Perspective. Am J Gastroenterol. 2016 Aug;111(8):1085-6. doi: 10.1038/ajg.2016.166. Epub 2016 May 10. PMID: 27166129.
Rückert-Eheberg IM, Nolde M, Ahn N, Tauscher M, Gerlach R, Güntner F, Günter A, Meisinger C, Linseisen J, Amann U, Baumeister SE. Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010-2018. Eur J Clin Pharmacol. 2022 Apr;78(4):657-667. doi: 10.1007/s00228-021-03257-z. Epub 2021 Dec 8. PMID: 34877614; PMCID: PMC8927002.
Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2018 Nov 19;10:2042098618809927. doi: 10.1177/2042098618809927. PMID: 31019676; PMCID: PMC6463334.
Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022 Apr;162(4):1334-1342. doi: 10.1053/j.gastro.2021.12.247. Epub 2022 Feb 17. PMID: 35183361.
Yibirin M, De Oliveira D, Valera R, Plitt AE, Lutgen S. Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus. 2021 Jan 18;13(1):e12759. doi: 10.7759/cureus.12759. PMID: 33614352; PMCID: PMC7887997.
Dharmarajan TS. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing. J Am Med Dir Assoc. 2021 Jan;22(1):15-22. doi: 10.1016/j.jamda.2020.09.046. Epub 2020 Dec 13. PMID: 33321078.
Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016 Nov 9;14(1):179. doi: 10.1186/s12916-016-0718-z. PMID: 27825371; PMCID: PMC5101793.
Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018 Nov;11(11):1123-1134. doi: 10.1080/17512433.2018.1531703. Epub 2018 Oct 10. PMID: 30295105.
Albarki H, Pun A, Paddle PM. What is the truth about proton pump inhibitors? Curr Opin Otolaryngol Head Neck Surg. 2020 Dec;28(6):376-384. doi: 10.1097/MOO.0000000000000663. PMID: 33109942.
Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M, Vega KJ. Potential proton pump inhibitor-related adverse effects. Ann N Y Acad Sci. 2020 Dec;1481(1):43-58. doi: 10.1111/nyas.14428. Epub 2020 Aug 6. Erratum in: Ann N Y Acad Sci. 2021 Mar;1487(1):74. PMID: 32761834.
Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Mujagic Z, Vila AV, Falony G, Vieira-Silva S, Wang J, Imhann F, Brandsma E, Jankipersadsing SA, Joossens M, Cenit MC, Deelen P, Swertz MA; LifeLines cohort study; Weersma RK, Feskens EJ, Netea MG, Gevers D, Jonkers D, Franke L, Aulchenko YS, Huttenhower C, Raes J, Hofker MH, Xavier RJ, Wijmenga C, Fu J. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016 Apr 29;352(6285):565-9. doi: 10.1126/science.aad3369. Epub 2016 Apr 28. PMID: 27126040; PMCID: PMC5240844..
Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020 Mar;51(5):505-526. doi: 10.1111/apt.15604. Epub 2020 Jan 28. PMID: 31990420.
Spechler SJ. Proton Pump Inhibitors: What the Internist Needs to Know. Med Clin North Am. 2019 Jan;103(1):1-14. doi: 10.1016/j.mcna.2018.08.001. Epub 2018 Oct 23. PMID: 30466666.
Castellana C, Pecere S, Furnari M, Telese A, Matteo MV, Haidry R, Eusebi LH. Side effects of long-term use of proton pump inhibitors: practical considerations. Pol Arch Intern Med. 2021 Jun 29;131(6):541-549. doi: 10.20452/pamw.15997. Epub 2021 May 13. PMID: 33982542.
Schnoll-Sussman F, Niec R, Katz PO. Proton Pump Inhibitors: The Good, Bad, and Ugly. Gastrointest Endosc Clin N Am. 2020 Apr;30(2):239-251. doi: 10.1016/j.giec.2019.12.005. Epub 2020 Jan 13. PMID: 32146944.
Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, Chiriac SA, Ciobica A, Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol. 2017 Sep 21;23(35):6500-6515. doi: 10.3748/wjg.v23.i35.6500. PMID: 29085200; PMCID: PMC5643276.
Cao F, Chen CX, Wang M, Liao HR, Wang MX, Hua SZ, Huang B, Xiong Y, Zhang JY, Xu YL. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect. 2018 Jan;98(1):4-13. doi: 10.1016/j.jhin.2017.08.017. Epub 2017 Aug 24. PMID: 28842261.
Seo SI, You SC, Park CH, Kim TJ, Ko YS, Kim Y, Yoo JJ, Kim J, Shin WG. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model. J Gastroenterol Hepatol. 2020 Aug;35(8):1325-1330. doi: 10.1111/jgh.14983. Epub 2020 Jan 29. PMID: 31970824..
Hafiz RA, Wong C, Paynter S, David M, Peeters G. The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis. Ann Pharmacother. 2018 Jul;52(7):613-622. doi: 10.1177/1060028018760569. Epub 2018 Feb 18. PMID: 29457492.
Weitsman S, Celly S, Leite G, Mathur R, Sedighi R, Barlow GM, Morales W, Sanchez M, Parodi G, Villanueva-Millan MJ, Rezaie A, Pimentel M. Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes. Dig Dis Sci. 2022 Jan;67(1):224-232. doi: 10.1007/s10620-021-06857-y. Epub 2021 Feb 3. PMID: 33534012.
Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018 Jan;53(1):27-36. doi: 10.1007/s00535-017-1371-9. Epub 2017 Aug 2. PMID: 28770351.
Yu T, Tang Y, Jiang L, Zheng Y, Xiong W, Lin L. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis. Dig Liver Dis. 2016 Apr;48(4):353-9. doi: 10.1016/j.dld.2015.12.009. Epub 2015 Dec 29. PMID: 26795544.
Xun X, Yin Q, Fu Y, He X, Dong Z. Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia: An Updated Meta-analysis. Ann Pharmacother. 2022 May;56(5):524-532. doi: 10.1177/10600280211039240. Epub 2021 Aug 23. PMID: 34425689.
Zirk-Sadowski J, Masoli JA, Delgado J, Hamilton W, Strain WD, Henley W, Melzer D, Ble A. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. J Am Geriatr Soc. 2018 Jul;66(7):1332-1338. doi: 10.1111/jgs.15385. Epub 2018 Apr 20. PMID: 29676433; PMCID: PMC6099478.
Nguyen PA, Islam M, Galvin CJ, Chang CC, An SY, Yang HC, Huang CW, Li YJ, Iqbal U. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. Int J Qual Health Care. 2020 Jun 17;32(5):292-299. doi: 10.1093/intqhc/mzaa041. PMID: 32436582.
Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol. 2020 Oct;115(10):1707-1715. doi: 10.14309/ajg.0000000000000798. PMID: 32852340; PMCID: PMC7473791.
Lee SW, Ha EK, Yeniova AÖ, Moon SY, Kim SY, Koh HY, Yang JM, Jeong SJ, Moon SJ, Cho JY, Yoo IK, Yon DK. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021 Jan;70(1):76-84. doi: 10.1136/gutjnl-2020-322248. Epub 2020 Jul 30. PMID: 32732368.
Fatima K, Almas T, Lakhani S, Jahangir A, Ahmed A, Siddiqui A, Rahim A, Qureshi SA, Arshad Z, Golani S, Musheer A. The Use of Proton Pump Inhibitors and COVID-19: A Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2022 Feb 28;7(3):37. doi: 10.3390/tropicalmed7030037. PMID: 35324584; PMCID: PMC8950138.
Linder L, Tamboue C, Clements JN. Drug-Induced Vitamin B12 Deficiency: A Focus on Proton Pump Inhibitors and Histamine-2 Antagonists. J Pharm Pract. 2017 Dec;30(6):639-642. doi: 10.1177/0897190016663092. Epub 2016 Aug 12. PMID: 27520327.
Porter KM, Hoey L, Hughes CF, Ward M, Clements M, Strain J, Cunningham C, Casey MC, Tracey F, O'Kane M, Pentieva K, McAnena L, McCarroll K, Laird E, Molloy AM, McNulty H. Associations of atrophic gastritis and proton-pump inhibitor drug use with vitamin B-12 status, and the impact of fortified foods, in older adults. Am J Clin Nutr. 2021 Oct 4;114(4):1286-1294. doi: 10.1093/ajcn/nqab193. PMID: 34134144; PMCID: PMC8488868.
Mumtaz H, Ghafoor B, Saghir H, Tariq M, Dahar K, Ali SH, Waheed ST, Syed AA. Association of Vitamin B12 deficiency with long-term PPIs use: A cohort study. Ann Med Surg (Lond). 2022 Sep 26;82:104762. doi: 10.1016/j.amsu.2022.104762. PMID: 36268318; PMCID: PMC9577826.
Chinzon D, Domingues G, Tosetto N, Perrotti M. SAFETY OF LONG-TERM PROTON PUMP INHIBITORS: FACTS AND MYTHS. Arq Gastroenterol. 2022 Apr-Jun;59(2):219-225. doi: 10.1590/S0004-2803.202202000-40. PMID: 35830032.
Lerman TT, Cohen E, Sochat T, Goldberg E, Goldberg I, Krause I. Proton pump inhibitor use and its effect on vitamin B12 and homocysteine levels among men and women: A large cross-sectional study. Am J Med Sci. 2022 Dec;364(6):746-751. doi: 10.1016/j.amjms.2022.07.006. Epub 2022 Jul 24. PMID: 35896125.
Srinutta T, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine (Baltimore). 2019 Nov;98(44):e17788. doi: 10.1097/MD.0000000000017788. PMID: 31689852; PMCID: PMC6946416.
Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M, Franco OH, Kuipers EJ, Hofman A, Zietse R, Stricker BH, Hoorn EJ. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis. 2015 Nov;66(5):775-82. doi: 10.1053/j.ajkd.2015.05.012. Epub 2015 Jun 26. PMID: 26123862.
Gommers LMM, Hoenderop JGJ, de Baaij JHF. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol (Oxf). 2022 Aug;235(4):e13846. doi: 10.1111/apha.13846. Epub 2022 Jun 14. PMID: 35652564; PMCID: PMC9539870.
Al Ali HS, Jabbar AS, Neamah NF, Ibrahim NK. Long-Term Use of Omeprazole: Effect on Haematological and Biochemical Parameters. Acta Med Indones. 2022 Oct;54(4):585-594. PMID: 36624706.
Liu J, Li X, Fan L, Yang J, Wang J, Sun J, Wang Z. Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis. Life Sci. 2019 Feb 1;218:213-223. doi: 10.1016/j.lfs.2018.12.058. Epub 2018 Dec 31. PMID: 30605646.
Poly TN, Islam MM, Yang HC, Wu CC, Li YJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019 Jan;30(1):103-114. doi: 10.1007/s00198-018-4788-y. Epub 2018 Dec 12. PMID: 30539272
da Maia TF, de Camargo BG, Pereira ME, de Oliveira CS, Guiloski IC. Increased Risk of Fractures and Use of Proton Pump Inhibitors in Menopausal Women: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022 Oct 19;19(20):13501. doi: 10.3390/ijerph192013501. PMID: 36294082; PMCID: PMC9603342.
Hamano H, Niimura T, Horinouchi Y, Zamami Y, Takechi K, Goda M, Imanishi M, Chuma M, Izawa-Ishizawa Y, Miyamoto L, Fukushima K, Fujino H, Tsuchiya K, Ishizawa K, Tamaki T, Ikeda Y. Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway. Toxicol Lett. 2020 Jan;318:86-91. doi: 10.1016/j.toxlet.2019.10.016. Epub 2019 Oct 24. PMID: 31669099.
Sharma N, Chau WY, Dobruskin L. Effect of long-term proton pump inhibitor therapy on hemoglobin and serum iron levels after sleeve gastrectomy. Surg Obes Relat Dis. 2019 Oct;15(10):1682-1689. doi: 10.1016/j.soard.2019.06.019. Epub 2019 Jun 27. PMID: 31422079.
Ali MD. Proton Pump Inhibitors' Use and Risk of Iron Deficiency Anaemia: A Systematic Review and Meta-analysis. Curr Rev Clin Exp Pharmacol. 2023;18(2):158-166. doi: 10.2174/2772432817666220307121220. PMID: 35255801.
Boxer M. Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors. EJHaem. 2020 Sep 1;1(2):548-551. doi: 10.1002/jha2.96. PMID: 35845020; PMCID: PMC9175665.
Nochaiwong S, Ruengorn C, Awiphan R, Koyratkoson K, Chaisai C, Noppakun K, Chongruksut W, Thavorn K. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018 Feb 1;33(2):331-342. doi: 10.1093/ndt/gfw470. PMID: 28339835.
Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: Risks of long-term use. J Gastroenterol Hepatol. 2017 Jul;32(7):1295-1302. doi: 10.1111/jgh.13737. PMID: 28092694.
Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study. Pharmacotherapy. 2019 Apr;39(4):443-453. doi: 10.1002/phar.2235. Epub 2019 Mar 21. PMID: 30779194; PMCID: PMC6453745.
Al-Aly Z, Maddukuri G, Xie Y. Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe. Am J Kidney Dis. 2020 Apr;75(4):497-507. Epub 2019 Oct 10. doi: 10.1053/j.ajkd.2019.07.012. PMID: 31606235
Lazarus B. Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med. 2016. Feb;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193. PMID: 26752337
Wang J, Wu Y, Bi Q, Zheng X, Zhang J, Huang W. Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis. Hepatol Int. 2020 May;14(3):385-398. doi: 10.1007/s12072-019-10010-3. Epub 2020 Jan 7. PMID: 31912308
Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020 Jun;76(6):851-866. doi: 10.1007/s00228-020-02854-8. Epub 2020 Mar 14. PMID: 32172363
Liu YB, Chen MK. The impact of proton pump inhibitors in liver diseases and the effects on the liver. J Dig Dis. 2022 Apr;23(4):196-208. doi: 10.1111/1751-2980.13093. Epub 2022 Apr 26. PMID: 35357775
Uździcki A, Awgul S, Słuczanowska-Głąbowska S. Chosen reports on the risks and complications associated with proton pump inhibitor therapy. Farmacja Współczesna 2017; 10: 168-176, https://www.akademiamedycyny.pl/wp-content/uploads/2018/01/10.pdf
Murtaza G, Khalid MF, Mungo NA. Recurrent Pantoprazole-Associated Pancreatitis. Am J Ther. 2018 Jul/Aug;25(4):e492-e493. doi: 10.1097/MJT.0000000000000567.PMID: 28282309
Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020 Apr;55(4):453-461. doi: 10.1007/s00535-019-01652-z. Epub 2019 Dec 6.PMID: 31811561
Poly TN, Islam MM, Walther BA, Lin MC, Li YJ. Proton Pump Inhibitors Use and the Risk of Pancreatic Cancer: Evidence from Eleven Epidemiological Studies, Comprising 1.5 Million Individuals. Cancers (Basel). 2022 Oct 30;14(21):5357. doi: 10.3390/cancers14215357.PMID: 36358776
Alkhushaym N, Almutairi AR, Althagafi A, Fallatah SB, Oh M, Martin JR, Babiker HM, McBride A, Abraham I. Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. Expert Opin Drug Saf. 2020 Mar;19(3):327-334. doi: 10.1080/14740338.2020.1715939. Epub 2020 Jan 21.PMID: 31928106
Ciardullo S, Rea F, Savaré L, Morabito G, Perseghin G, Corrao G. Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study. J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2671-e2679. doi: 10.1210/clinem/dgac231.PMID: 35428888
Chen Y, Hu L, Sun C, Bao J, Liu J, Bhan C, Kim KY, Manem R, Thapa P, Ma S, Liu M, Cheng X, Cheng C, Zhou Q. Will Proton Pump Inhibitors Increase the Risk of Diabetes Mellitus? A Systemic Review and Meta-Analysis. Turk J Gastroenterol. 2022 Jun;33(6):497-504. doi: 10.5152/tjg.2022.21480.PMID: 35786618
Manolis AA, Manolis TA, Melita H, Katsiki N, Manolis AS. Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries?. Eur J Intern Med. 2020 Feb;72:15-26. doi: 10.1016/j.ejim.2019.11.017. Epub 2019 Nov 30.PMID: 31796246
Shiraev TP, Bullen A. Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review. Heart Lung Circ. 2018 Apr;27(4):443-450. doi: 10.1016/j.hlc.2017.10.020. Epub 2017 Nov 20.PMID: 29233498
Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G.Stroke. Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines A Systematic Review and Meta-Analysis. 2018 Feb;49(2):312-318. doi: 10.1161/STROKEAHA.117.019166. Epub 2018 Jan 16.PMID: 29339434
Casula M, Scotti L, Galimberti F, Mozzanica F, Tragni E, Corrao G, Catapano AL. Use of proton pump inhibitors and risk of ischemic events in the general population. Atherosclerosis. 2018 Oct;277:123-129. doi: 10.1016/j.atherosclerosis.2018.08.035. Epub 2018 Aug 27.PMID: 30212680
Jeridi D, Pellat A, Ginestet C, Assaf A, Hallit R, Corre F, Coriat R. The Safety of Long-Term Proton Pump Inhibitor Use on Cardiovascular Health: A Meta-Analysis. J Clin Med. 2022 Jul 15;11(14):4096. doi: 10.3390/jcm11144096.PMID: 35887860
Batchelor R, Gilmartin JF, Kemp W, Hopper I, Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. J Gastroenterol Hepatol. 2017 Aug;32(8):1426-1435. doi: 10.1111/jgh.13750.PMID: 28128476
Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, Doblhammer G, Haenisch B. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016 Apr;73(4):410-6. doi: 10.1001/jamaneurol.2015.4791.PMID: 26882076
Choi HG, Kim JH, Kim JH, Kim ES, Park HY, Min KW, Kwon MJ. Associations between proton pump inhibitors and Alzheimer’s disease: a nested case–control study using a Korean nationwide health screening kohort. Alzheimers Res Ther. 2022 Jul 1;14(1):91. doi: 10.1186/s13195-022-01032-5.PMID: 35773740
Goldstein FC, Steenland K, Zhao L, Wharton W, Levey AI, Hajjar I. Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia. J Am Geriatr Soc. 2017 Sep;65(9):1969-1974. doi: 10.1111/jgs.14956. Epub 2017 Jun 7.PMID: 28590010
Weiss A, Gingold-Belfer R, Boltin D, Beloosesky Y, Koren-Morag N, Meyerovitch J, Sharon E, Schmilovitz-Weiss H. Chronic omeprazole use in the elderly is associated with decreased risk of dementia and cognitive decline. Dig Liver Dis. 2022 May;54(5):622-628. doi: 10.1016/j.dld.2021.11.018. Epub 2021 Dec 20.PMID: 34949554
Ahn N, Nolde M, Krause E, Güntner F, Günter A, Tauscher M, Gerlach R, Meisinger C, Linseisen J, Baumeister SE, Rückert-Eheberg IM. Do proton pump inhibitors increase the risk of dementia? A systematic review, meta-analysis and bias analysis. Br J Clin Pharmacol. 2023 Feb;89(2):602-616. doi: 10.1111/bcp.15583. Epub 2022 Nov 23.PMID: 36331350
Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015 Sep;42(6):649-63. doi: 10.1111/apt.13324. Epub 2015 Jul 16.PMID: 26177572
Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017 Oct 30;7(10):e017739. doi: 10.1136/bmjopen-2017-017739.PMID: 29084798
Lin, J.-L., Lin, J.-X., Zheng, C.-H., Xie, J.-W., Wang, J.-B., Lu, J., Chen, Q.-Y., Cao, L.-L., Lin, M., Li, P., & Huang, C.-M. (2020). Long-term proton pump inhibitor use and the incidence of gastric cancer: A systematic review and meta-analysis. Journal of Gastric Surgery, 2(1), 1–11. https://doi.org/10.36159/jgs.v2i1.17
Trinh VQ, Shi C, Ma C. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis. Histopathology. 2020 Dec;77(6):865-876. doi: 10.1111/his.14220. Epub 2020 Sep 20.PMID: 32702178
Piovani D, Tsantes AG, Schünemann HJ, Bonovas S. Meta-analysis: Use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression. Aliment Pharmacol Ther. 2023 Mar;57(6):653-665. doi: 10.1111/apt.17360. Epub 2022 Dec 31.PMID: 36585832
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Izabela Wolanin, Bartłomiej Zielonka, Barbara Dengler, Karolina Madej, Marta Wolanin, Bartłomiej Stachyra, Cezary Stawikowski, Aleksandra Osińska, Ilona Kowalczyk, Aleksandra Krasa
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 470
Number of citations: 0
